Document is current
Any future updates will be listed below
-
Authors
Marconato, Luca
Palla, Giovanni
Yamauchi, Kevin A. https://orcid.org/0000-0002-7818-1388
Virshup, Isaac
Heidari, Elyas
Treis, Tim https://orcid.org/0000-0002-9686-4799
Vierdag, Wouter-Michiel https://orcid.org/0000-0003-1666-5421
Toth, Marcella
Stockhaus, Sonja https://orcid.org/0009-0005-7712-8154
Shrestha, Rahul B.
Rombaut, Benjamin https://orcid.org/0000-0002-4022-715X
Pollaris, Lotte https://orcid.org/0000-0002-9509-9386
Lehner, Laurens
Vöhringer, Harald
Kats, Ilia https://orcid.org/0000-0001-5220-5671
Saeys, Yvan https://orcid.org/0000-0002-0415-1506
Saka, Sinem K. https://orcid.org/0000-0002-5017-379X
Huber, Wolfgang https://orcid.org/0000-0002-0474-2218
Gerstung, Moritz
Moore, Josh https://orcid.org/0000-0003-4028-811X
Theis, Fabian J. https://orcid.org/0000-0002-2419-1943
Stegle, Oliver https://orcid.org/0000-0002-8818-7193
- License Information
-
More Information
Article History
Received: 15 May 2023
Accepted: 14 February 2024
First Online: 20 March 2024
Competing interests
: J.M. holds equity in Glencoe Software, which builds products based on OME–NGFF. F.J.T. consults for Immunai, Inc., Singularity Bio B.V., CytoReason Ltd, Cellarity and Omniscope and has ownership interest in Dermagnostix GmbH and Cellarity. O.S. is a paid consultant of Insitro, Inc., S.K.S. is a consulting scientific cofounder for Digital Biology, Inc. The remaining authors declare no competing interests.
